BPC-157 + TB-500

Identity and composition

BPC-157 + TB-500 it is a combination of two distinct research peptides that are studied, mainly in preclinical models, for their role in angiogenesis and tissue repair. As they are two separate molecules, the combination it does not possess a single chemical identity: no single CAS, molecular weight, formula, or sequence applies to the combination.

In terms of the identity of each component:

• BPC-157 (Body Protection Compound-157) is a pentadecapeptide (15-amino-acid chain) derived from a partial sequence of a gastric juice protein. In open source, PubChem (CID 9941957) lists for BPC-157 the molecular formula C62H98N16O22.
• TB-500 is a synthetic fragment corresponding to the actin-binding motif (seven amino acids) of thymosin beta-4 (Tβ4), a complete 43-amino-acid protein from which it is derived.

The values of CAS, molecular weight and the exact sequences of both peptides, as well as the molecular formula of TB-500, were not confirmed in open PubChem/DrugBank data sheets in this research, so they are omitted so as not to present unverified data.

Product for research use.

Mechanism of action

The two peptides act through distinct pathways that converge on angiogenesis and tissue repair, as described in preclinical mechanistic literature.

BPC-157: in preclinical models it promotes angiogenesis by upregulating the VEGFR2 receptor, inducing its internalization and activating the VEGFR2-Akt-eNOS pathway, with an increase in nitric oxide production (PMID 27847966). A complementary mechanism described is the activation of the Src-Caveolin-1-eNOS pathway: BPC-157 phosphorylates Src and Cav-1, reduces the Cav-1/eNOS binding, and releases eNOS to generate nitric oxide, modulating vasomotor tone (PMID 33051481).

TB-500: corresponds to the actin-binding motif of thymosin beta-4. Thymosin beta-4 is a G-actin-sequestering protein, and its seven-amino-acid actin-binding motif has been described as essential for its angiogenic activity, promoting the migration of endothelial cells and vascular sprouting (PMID 14500546).

Taken together, the available evidence on these mechanisms comes from in vitro studies and animal models; its translation to humans remains unestablished.

Pharmacokinetics

No confirmed pharmacokinetic data are available in an open primary source for either of the two peptides or for the combination. Parameters such as half-life, bioavailability, or elimination dynamics could not be verified in this research, so no figures are reported. Any quantitative characterization of the pharmacokinetics of BPC-157 + TB-500 must be considered not established.

Scientific evidence

The available evidence is mostly preclinical (in vitro and animal models), not clinical. For BPC-157, research has focused on tissue repair, angiogenesis, and healing of tendon, muscle, and gastrointestinal mucosa, almost all in rodents and cell cultures (PMID 27847966; PMID 33051481). For TB-500 / thymosin beta-4, the preclinical literature covers wound healing, angiogenesis, and cell migration, with full-length thymosin beta-4 explored in early phases of repair (PMID 14500546).

No clinical trials evaluating the BPC-157 + TB-500 combination were identified. Its combined use has no published efficacy or safety data in humans. None of these compounds is approved as a drug; they are handled as research compounds. The preliminary evidence must be interpreted with caution and does not permit extrapolating results to humans.

Research applications

Product for research use.

• Ideal for: in vitro and preclinical studies oriented toward exploring mechanisms of angiogenesis, nitric oxide signaling (VEGFR2 and Src-Cav-1-eNOS pathways), endothelial cell migration and tissue-repair processes, as reference material in the laboratory.
• Not applicable for: clinical use, therapeutic use, diagnosis, or any clinical application. There are no efficacy or safety data in humans for the combination, so it must not be used outside a controlled research context.

Research protocols

No dosing protocols from studies were identified that support specific numerical schemes for the BPC-157 + TB-500 combination in the reviewed evidence, so no study doses are reported.

The available presentations of the product (5 mg + 5 mg y 10 mg + 10 mg) correspond to the quantity of lyophilized peptide per vial for research handling purposes, and do not represent a dose recommendation or a validated regimen. The design of any experimental protocol remains at the discretion of the responsible investigator.

Reconstitution

As a general standard laboratory guide, lyophilized peptides are usually reconstituted with bacteriostatic water (water for injection with approximately 0.9% benzyl alcohol as a preservative), which allows multiple withdrawals while maintaining the relative sterility of the vial.

General steps:

• Let the lyophilized vial reach room temperature before opening it.
• Add the bacteriostatic water, letting it run slowly down the vial wall, without injecting the stream directly onto the powder.
• Do not shake; gently swirl the vial until fully dissolved.
• The diluent volume is chosen according to the working concentration desired for the experiment.

This is qualitative handling guidance; it does not constitute instructions for human use.

Stability and storage

As a laboratory handling standard:

• Lyophilized (unreconstituted): peptides in powder form are more stable and are usually stored refrigerated and, for long-term storage, frozen, protected from light and moisture.
• Reconstituted (in solution): stability decreases once in solution; it is advisable to keep it refrigerated and use it within a relatively short window, avoiding repeated freeze-thaw cycles.

These ranges are a general handling guide for research compounds and do not replace the batch specifications.

Safety profile

Clinical safety profile: not established. No controlled human safety data were identified for the combination nor for each peptide separately in open primary sources in this research.

A caution point documented in the mechanistic literature: both the pro-angiogenic signaling of BPC-157 (via VEGFR2) and the angiogenic activity of thymosin beta-4 / TB-500 could be relevant in the promotion of vascularization. Induced angiogenesis has been noted in the literature as a double-edged mechanism because of its possible relevance in tumor contexts, which motivates theoretical caution regarding scenarios of unwanted tissue growth.

Since no established safety profile exists, the material must be handled only under research conditions and not in human beings.

Comparative context

Compared with other peptides of its class, BPC-157 + TB-500 combines two molecules with different origins and pathways that nonetheless converge on angiogenesis and repair:

• BPC-157 acts mainly through nitric oxide signaling, via the VEGFR2-Akt-eNOS and Src-Caveolin-1-eNOS pathways, with an effect on vasomotor tone.
• TB-500 is derived from the actin-binding domain of thymosin beta-4, associated with G-actin sequestration and cell migration.

The rationale for combining them, at the preclinical level, is that they contribute complementary mechanisms (vascular signaling on one hand and actin dynamics/cell migration on the other). Unlike full thymosin beta-4—a 43-amino-acid protein explored in early phases of repair—TB-500 represents only its active actin-binding motif. It is important to note that none of these compounds is approved as a drug and that there are no studies of the combination in humans.

History and development

BPC-157 arises from research on gastrointestinal tract protective proteins: it is a pentadecapeptide derived from a partial sequence of a protein present in gastric juice, studied in preclinical models for its effects on tissue repair, angiogenesis and vascular protection.

TB-500 derives from the thymosin beta-4 (Tβ4), a 43-amino-acid G-actin-sequestering protein with activity in wound healing, angiogenesis and cell migration. TB-500 corresponds specifically to the seven-amino-acid actin-binding motif, identified in research as essential for the angiogenic activity of thymosin beta-4 (PMID 14500546).

Combining the two as research material is a laboratory practice; it does not derive from an approved pharmaceutical development program and lacks clinical trials evaluating the two peptides together.

FAQ

Customer reviews

Average rating: 4.8 out of 5, based on 13 customer ratings.

Scientific references (6)

There is no peer-reviewed literature on BPC-157 + TB-500 as a combination. What follows is the literature for each component separately, with its PubMed identifier:

• About BPC-157: Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats (Xue, et al. · World Journal of Gastroenterology · 2004) PMID 15052688.
• About TB-500: Thymosin beta4 accelerates wound healing (Malinda, et al. · Journal of Investigative Dermatology · 1999) PMID 10469335.
• About BPC-157: Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157 (Sikiric, et al. · Current Medicinal Chemistry · 2012) PMID 22300085.
• About TB-500: Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications (Goldstein, et al. · Expert Opinion on Biological Therapy · 2012) PMID 22074294.
• About BPC-157: The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (Chang, et al. · Journal of Applied Physiology · 2011) PMID 21030672.
• About TB-500: Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury (Sosne, et al. · Experimental Eye Research · 2002) PMID 11950239.

Otras presentaciones de BPC-157 + TB-500

• BPC-157 + TB-500 Blend

Guides and articles about BPC-157 + TB-500

Lecturas del blog de EXOMA que la editorial asoció a este compuesto:

• Oral Research Compounds: A Review of BPC-157, TB-500, Cabergoline, GW-501516, and Clenbuterol

Other related research peptides

• BPC-157 + TB-500 + KPV
• KPV
• PTD-DBM
• TB-500
• TB-500 FRAG
• ACE-031
• ARA-290
• BPC-157